HIV damages the body in stages, beginning with a burst of viral replication that strips immune cells from the gut lining and seeds reservoirs throughout the immune system, then settling into a years-long chronic phase where persistent inflammation quietly injures the heart, brain, kidneys, liver, lungs, and bones. Even when antiretroviral therapy suppresses the virus to undetectable levels, low-grade immune activation continues, and DNA-methylation studies indicate that people living with HIV are roughly five to seven years biologically older than their chronological age suggests. Understanding each stage and the organs it puts at risk helps explain why early treatment matters and why HIV care extends well beyond managing the virus itself.
The Acute Phase and the Gut as Ground Zero
Within days to weeks of infection, HIV replicates explosively. The virus has a strong preference for activated CD4 T cells, which are concentrated in the gut-associated lymphoid tissue. During this acute phase, the virus wipes out a massive share of CD4 cells in the intestinal mucosa. This early, severe mucosal depletion triggers a cascade: the tight junctions between cells lining the intestinal wall break down, enterocytes (the cells forming that barrier) die off, and the composition of gut bacteria shifts toward more harmful species.1PubMed Central. Microbial translocation in the pathogenesis of HIV infection and AIDS The result is that bacteria and bacterial fragments leak through the damaged gut wall into the bloodstream, a process called microbial translocation.2PubMed Central. Microbial translocation and microbiome dysbiosis in HIV-associated immune activation
This leaky gut is not a temporary inconvenience. It becomes a sustained source of fuel for system-wide inflammation. Even people on effective antiretroviral therapy show elevated markers of microbial translocation, and this inflammation is now understood as a central driver of organ damage throughout the body.3PubMed Central. Systemic effects of inflammation on health during chronic HIV infection The destruction that begins in the gut during the first weeks of infection sets the stage for problems that play out over decades.
Chronic Inflammation and Why It Persists on Treatment
Once antiretroviral therapy drives the virus to undetectable levels in the blood, you might expect the immune system to calm down. It does, but not entirely. Chronic immune activation and inflammation remain one of the defining features of treated HIV, and they are strongly predictive of disease progression, organ damage, and death.4PubMed Central. Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection Part of the reason is that latently infected cells survive indefinitely. When activated CD4 T cells become infected and then revert to a resting memory state, the viral DNA hides inside them, silenced but intact. Because memory T cells can live for decades, this reservoir persists even in patients on potent therapy.5PubMed Central. HIV latency
That hidden reservoir, combined with ongoing microbial translocation from the gut and immune cells that have become metabolically dysregulated and exhausted, keeps the inflammatory furnace lit at a low burn. Over time, this smoldering inflammation reaches virtually every organ system.
Cardiovascular Damage
Heart disease is one of the most studied complications of chronic HIV. The virus does not need to infect heart tissue directly; instead, persistent inflammation promotes arterial stiffness, plaque buildup, and structural changes to the heart. A comparative study in Tanzania found that HIV infection was independently associated with elevated arterial stiffness, and that this stiffness was in turn linked to echocardiographic changes including altered heart filling pressures and increased heart-muscle mass.6PubMed Central. Arterial stiffness in people with HIV: a cross-sectional, comparative study with echocardiographic outcomes in Tanzania Newer antiretroviral regimens, particularly those based on integrase inhibitors, have reduced the severe metabolic side effects of older drugs, but they come with their own concerns: these regimens are associated with weight gain and growth of specific fat deposits around the heart and blood vessels, which may independently contribute to cardiovascular risk.7PubMed Central. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions
The Brain and Nervous System
HIV can enter the central nervous system during early infection, and once there, it establishes a separate compartment where the virus and its inflammatory effects are partially shielded from treatment. Persistent infection and inflammation in the brain contribute to a range of cognitive problems grouped under the term HIV-associated neurocognitive disorder, or HAND.8Nature Reviews Neurology. HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment In the era of effective antiretroviral therapy, the most severe form (HIV-associated dementia) has become far less common, but milder forms, including difficulty with concentration, memory, and processing speed, remain surprisingly prevalent. Many people living with HIV report feeling cognitively “off” even when their viral load is undetectable, and brain imaging studies show ongoing low-level inflammation that correlates with these complaints.
Kidney Disease
The kidneys are among the organs HIV can infect directly. The virus enters specialized kidney cells called podocytes and tubular epithelial cells, and the resulting damage can lead to a distinctive form of kidney disease known as HIV-associated nephropathy, or HIVAN.9Nature Reviews Nephrology. HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment HIVAN classically appears in younger adults of African ancestry with advanced HIV disease, and this genetic link is now well understood: two risk variants in the APOL1 gene play a critical role in who develops the disease.10PubMed Central. Pathogenesis of HIV-associated nephropathy in children and adolescents: taking a hard look 40 years later in the era of gene-environment interactions Beyond HIVAN, HIV-related immune complex disease is the second most common kidney diagnosis found on biopsy, and chronic kidney disease in people with HIV is shaped by an interplay of viral factors, genetic susceptibility, and environmental exposures.11PubMed Central. HIV and chronic kidney disease
Liver and Metabolic Health
Nonalcoholic fatty liver disease has emerged as a major concern for people living with HIV. Depending on how it is measured, fatty liver disease occurs in roughly 30 to 65 percent of this population, driven by metabolic syndrome, abnormal fat distribution, the virus itself, some antiretroviral drugs, and changes to the gut microbiome.12PubMed Central. Fatty liver disease in persons with HIV infection An interesting twist is that fatty liver appears to progress faster in people with HIV alone than in those co-infected with HIV and hepatitis C, and in the HIV mono-infected group, fat accumulation in the liver was a strong predictor of progressing to liver fibrosis.13Journal of Hepatology. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis Weight gain, which is common on modern antiretroviral regimens, independently predicts worsening fibrosis as well.14PubMed Central. The effect of weight gain and metabolic dysfunction-associated steatotic liver disease on liver fibrosis progression and regression in people with HIV
The metabolic picture extends beyond the liver. Earlier antiretroviral regimens, particularly drugs like stavudine and zidovudine, caused a striking redistribution of body fat: subcutaneous fat wasted away while abdominal fat accumulated, a condition called lipodystrophy. This was accompanied by insulin resistance and unhealthy lipid profiles. The underlying metabolic disturbance involves accelerated breakdown of fat and increased repackaging of fatty acids in the liver.15PubMed. Metabolic basis of HIV-lipodystrophy syndrome Newer drugs have largely eliminated the most severe forms of lipodystrophy, but the fat-related effects of older drugs do not always reverse after switching, and current regimens bring weight gain with their own metabolic consequences.7PubMed Central. Lipodystrophy in HIV: Evolving Challenges and Unresolved Questions
Lung Disease Beyond Infections
In the early years of the epidemic, lung disease in HIV meant pneumonia. That has changed. While opportunistic lung infections still occur in people with severely suppressed immune systems, noninfectious lung conditions have become common complications. HIV infection increases the risk of chronic obstructive pulmonary disease (COPD), emphysema, lung fibrosis, and pulmonary arterial hypertension.16PubMed Central. Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef A large study using French hospital data showed that even among younger adults (ages 30 to 49), HIV infection was independently associated with these conditions after accounting for smoking.17PubMed. Increasing burden of noninfectious lung disease in persons living with HIV: a 7-year study using the French nationwide hospital administrative database COPD in particular is frequent enough in the HIV population to warrant active screening and management.18PubMed. Non-infectious pulmonary disorders in HIV
Bone Loss
Bone mineral density tends to be lower in people with HIV than in the general population, and this difference holds up even after adjusting for age, weight, race, and other confounders. In a study of men with or at risk for HIV, bone density at both the hip and lower spine was significantly reduced in HIV-positive participants compared to HIV-negative controls.19PubMed Central. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection Most of the bone loss appears to happen during two windows: while the virus is actively replicating (before treatment) and during the first months after starting antiretroviral therapy, when the recovering immune system ramps up the activity of cells that break down bone.20PubMed Central. Osteoporosis and HIV Infection Some antiretroviral classes, including protease inhibitors and certain backbone drugs, have been linked to additional bone loss, making the problem multifactorial: the virus, the immune recovery, the drugs, and traditional risk factors like smoking and vitamin D deficiency all play a role.21PubMed Central. Evaluation of Bone Mineral Density and Related Factors in Romanian HIV-Positive Patients Undergoing Antiretroviral Therapy
Blood Cell Production
HIV affects the bone marrow, where all blood cells are produced. Disruption of the bone marrow niche, through both direct and indirect effects of the virus, contributes to the low blood counts seen in many HIV patients.22Frontiers in Immunology. Consequences of HIV infection in the bone marrow niche This can show up as anemia, low platelet counts, or low white blood cell counts. In severe cases, HIV-related bone marrow suppression can lead to pancytopenia, where all three cell lines are depleted.23PubMed Central. Lost and Found: Misdiagnosis of AIDS-Related Bone Marrow Suppression As Neutropenic Fever and Benign Ethnic Neutropenia in a Patient With Congenital HIV These blood abnormalities can complicate diagnosis and treatment, especially when the underlying HIV infection is not yet recognized.
Skin as an Early Warning System
Skin problems are among the most visible signs of HIV-related immune suppression. Papular pruritic eruption, the most common HIV-specific skin condition, produces intensely itchy bumps on the limbs, trunk, and sometimes face. The itch and severity worsen as CD4 counts drop. Xerosis, or severe dry skin, results from damage to the skin’s barrier function, with changes in lipid content in the outer skin layers. It is a major cause of premature skin aging in people with HIV. Eosinophilic folliculitis, an inflammatory eruption around hair follicles, is most common at lower CD4 counts and is thought to involve an exaggerated immune response to antigens in the oil glands.24PubMed Central. A Comprehensive Review on HIV-Associated Dermatologic Manifestations: From Epidemiology to Clinical Management Because these conditions tend to track with immune status, their appearance or worsening can serve as a clinical signal that the virus is not being adequately controlled.
When the Immune System Collapses
Without treatment, the CD4 count eventually falls below 200 cells per cubic millimeter, the threshold that defines AIDS. At this point, infections that a healthy immune system would easily contain become life-threatening. Pneumocystis pneumonia, toxoplasmosis, and Mycobacterium avium complex infections all surge in frequency once CD4 counts drop below 200. At counts below 50, the risks expand further to include cytomegalovirus retinitis, central nervous system lymphoma, and disseminated fungal infections.25PubMed Central. Diagnosing HIV-related disease: using the CD4 count as a guide In one study, circulating CD4 counts were below 200 before 46 out of 49 episodes of Pneumocystis pneumonia, all 8 episodes of cytomegalovirus pneumonia, and all 7 episodes of Cryptococcus infection.26PubMed. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection
These opportunistic infections are not just markers of immune collapse; they cause their own organ damage. Toxoplasmosis creates brain abscesses. Cytomegalovirus can destroy the retina, colon, or adrenal glands. Mycobacterium avium complex can infiltrate the liver, bone marrow, and lymph nodes. The cascade of infections compounds the organ damage the virus has already been quietly causing through inflammation.
The Paradox of Immune Recovery
Starting antiretroviral therapy when CD4 counts are very low introduces another risk. As the immune system rebuilds, a small subset of patients experience immune reconstitution inflammatory syndrome, or IRIS, where the recovering immune system mounts an excessively aggressive response against infections that were already present, whether the person knew about them or not.27PubMed Central. Immune reconstitution inflammatory syndrome in HIV infection: taking the bad with the good Symptoms can range from swollen lymph nodes and fever to worsening of tuberculosis, fungal infections, or viral conditions. The underlying problem appears to be an imbalance: effector immune cells bounce back faster than the regulatory cells that keep them in check, leading to an overblown inflammatory response.28PubMed Central. HIV & immune reconstitution inflammatory syndrome (IRIS) IRIS is manageable in most cases, but it reinforces the point that starting treatment earlier, before the immune system is severely depleted, avoids some of the most dangerous complications.
Why Starting Treatment Early Protects Organs
The evidence for early antiretroviral therapy extends beyond suppressing the virus. In the landmark START trial, which randomized people with high CD4 counts to begin treatment immediately or wait, those who started early had a lower rate of new AIDS events and tuberculosis.29The Lancet Infectious Diseases. Prevention of HIV-1 infection with early antiretroviral therapy A liver-specific analysis of START showed that immediate treatment reduced the risk of developing liver fibrosis by about a third compared to deferred treatment, and was also more likely to reverse elevated fibrosis scores that were already present at baseline.30PubMed Central. Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial Long-term cardiovascular follow-up of the same trial, over a median of about nine years, did not find a clear overall difference in heart disease events between the early and deferred groups, though there was a possible benefit of early therapy in women.31Open Forum Infectious Diseases. Early versus deferred antiretroviral therapy initiation and long-term cardiovascular disease outcomes in people with HIV: The START study The takeaway is that early treatment’s organ-protecting benefits are real, but they vary by organ and possibly by sex.
Accelerated Biological Aging
One of the more striking findings in recent HIV research is that the virus appears to accelerate biological aging at the molecular level. Epigenetic clocks, which estimate biological age based on chemical modifications to DNA, show that people living with HIV are on average five to seven years biologically older than HIV-negative people of the same chronological age.32PubMed Central. Epigenetic aging is a hallmark of HIV pathogenesis and phenotypic outcomes This acceleration shows up in both blood and brain tissue, with brain tissue aging even faster, by an average of about seven years.33PubMed Central. HIV-1 Infection Accelerates Age According to the Epigenetic Clock The mechanisms feeding this aging include persistent viral activity, chronic immune activation, mitochondrial dysfunction, oxidative stress, and treatment-related metabolic effects.34Experimental Gerontology. Epigenetic clocks and accelerated biological aging in people living with HIV: Emerging mechanisms and clinical implications
This accelerated aging helps explain why people with HIV develop conditions like heart disease, kidney failure, osteoporosis, and cognitive decline at younger ages than their HIV-negative peers. It also means that standard age-based screening guidelines for these conditions may not be aggressive enough for people living with HIV.
Cancer Risk
HIV increases the risk of certain cancers through several overlapping routes: the direct oncogenic effects of the virus, immunosuppression that allows cancer-promoting viruses (like human papillomavirus and Epstein-Barr virus) to thrive, chronic inflammation, and higher rates of traditional cancer risk factors like smoking among people with HIV.35PubMed. Non-AIDS-defining cancers among HIV-infected patients AIDS-defining cancers like Kaposi sarcoma and certain lymphomas have declined dramatically with effective treatment, but non-AIDS-defining cancers, including lung, liver, and anal cancers, have become a growing concern as people with HIV live longer.
Clonal Hematopoiesis and Emerging Risks
A newer area of research involves clonal hematopoiesis, a condition where blood stem cells acquire mutations that give them a growth advantage, causing them to produce a disproportionate share of your blood cells. In the general population, clonal hematopoiesis becomes more common with age and is linked to an increased risk of blood cancers and cardiovascular disease. In people with HIV, even those on effective treatment, the residual chronic inflammation appears to create a favorable environment for these mutant clones to expand.36Nature Medicine. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults Multiple mechanisms likely contribute: immunodeficiency, higher rates of smoking, and the chronic antigenic stimulation that defines treated HIV may all modify the competitive landscape in the bone marrow.37Scientific Reports. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV Data from the REPRIEVE cardiovascular prevention trial in people with HIV further support the hypothesis that residual inflammation, acting through tumor suppressor and inflammasome pathways, drives high rates of clonal hematopoiesis in this population.38Blood Advances. Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial The clinical significance of this is still being worked out, but it may partly explain the elevated cardiovascular and cancer risks that persist even in virally suppressed individuals.